Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non-Current Deffered Revenue (2016 - 2021)

Syndax Pharmaceuticals (SNDX) has disclosed Non-Current Deffered Revenue for 7 consecutive years, with $10.9 million as the latest value for Q2 2021.

  • For Q2 2021, Non-Current Deffered Revenue fell 12.25% year-over-year to $10.9 million; the TTM value through Jun 2021 reached $10.9 million, down 12.25%, while the annual FY2020 figure was $11.6 million, 11.54% down from the prior year.
  • Non-Current Deffered Revenue hit $10.9 million in Q2 2021 for Syndax Pharmaceuticals, down from $11.2 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $16.8 million in Q4 2017 and bottomed at $10.9 million in Q2 2021.
  • Average Non-Current Deffered Revenue over 5 years is $13.6 million, with a median of $13.6 million recorded in 2017.
  • Year-over-year, Non-Current Deffered Revenue rose 17.86% in 2017 and then fell 12.58% in 2018.
  • Syndax Pharmaceuticals' Non-Current Deffered Revenue stood at $16.8 million in 2017, then dropped by 12.58% to $14.6 million in 2018, then decreased by 10.35% to $13.1 million in 2019, then fell by 11.54% to $11.6 million in 2020, then fell by 6.52% to $10.9 million in 2021.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $10.9 million, $11.2 million, and $11.6 million for Q2 2021, Q1 2021, and Q4 2020 respectively.